CD19-t-haNK

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameCD19-t-haNK
Drug Alias NameCD19-t-haNK(ImmunityBio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Africa
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNantkwest IncImmunitybio Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma

Other Information

ATC CodeN/A
Related LinksN/A